Eligibility for vericiguat in a real-world heart failure population according to trial, guidelines, and label criteria: Data from the Swedish Heart Failure Registry.
Ngoc V NguyenFelix LindbergLina BensonGiulia FerranniniEgidio ImbalzanoPeter G M MolUlf DahlströmGiuseppe M C RosanoJustin EzekowitzJaved ButlerLars H LundGianluigi SavaresePublished in: European journal of heart failure (2023)
In a large and contemporary real-world HFrEF cohort, we estimated that 21.4% of patients would be eligible for vericiguat according to the VICTORIA trial selection criteria, 47.4% based on guidelines and labeling. Eligibility for vericiguat translated into the selection of a population at high risk of morbidity/mortality. This article is protected by copyright. All rights reserved.
Keyphrases
- heart failure
- end stage renal disease
- study protocol
- phase iii
- ejection fraction
- clinical trial
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- clinical practice
- phase ii
- prognostic factors
- randomized controlled trial
- acute heart failure
- cardiac resynchronization therapy
- electronic health record
- type diabetes
- machine learning
- big data
- patient reported outcomes
- coronary artery disease
- deep learning